Paul Tudor Jones’s Gossamer Bio GOSS Stock Holding History

Paul Tudor Jones’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-300,000	Closed	-$930K	–	3887
2025 Q4	$930K	Buy	+300,000	New	+$856K	﹤0.01%	2322

Other funds holding GOSS

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

DIG

DeepCurrents Investment Group New York $3.3B AUM 12.57% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Paul Tudor Jones's GOSS Position: Q2 2026 in Review

Paul Tudor Jones increased its Gossamer Bio (GOSS) stake by 316% in Q2 2026, buying an estimated $102K and bringing the position to 479,581 shares worth $78.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3419.

Paul Tudor Jones first reported a position in GOSS in Q3 2020 and has held it in 18 quarters since. The position peaked at $561K in Q3 2022. 170 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

Paul Tudor Jones held 479,581 shares of Gossamer Bio worth $78.9K as of Q2 2026.
Paul Tudor Jones bought 364,344 Gossamer Bio shares in Q2 2026, an estimated $102K.
Gossamer Bio made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #3419 holding.
Paul Tudor Jones first reported a position in Gossamer Bio in Q3 2020 and has held it in 18 quarters since.
Paul Tudor Jones's Gossamer Bio position peaked at $561K in Q3 2022.
170 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.